Some immune cells overlap in cancer and Covid-19 so what can we learn from them in order to make an impact?
The December 17, 2010 issue of "Science" has the catchy of title of "Insights of the Decade", one of which is the ubiquitous role of inflammation in multiple chronic illnesses including cancer.
How can we go about improving cell therapy approaches?
When T cells stop working how can we get innate immune cells like NK cells to take up the slack and help track down tumours?
Tackling immune suppression in hematologic malignancies may improve outcomes with existing regimens
Reprogramming the tumour microenvironment - can it be done and if so, how and what should be targeted?
Can we learn from what a patient's tumour is telling us in terms of what the immune system is responding to in order to target it therapeutically?
Manipulating immune cells in order to harness great antitumour responses to immunotherapy
An expert interview with a leading immunologist who discusses two translational opportunities with potential for cancer immunotherapy
Insights from Transplantation & Cellular Therapy (TCT) meeting on the next generation of CAR T cells
Highlights from ASCO GU 2020 with some interesting targets and emerging molecules to consider
In this post we look at an emerging research area that will be important to address if CAR T cell therapy is to be effective in solid tumours
CAR T cell therapy for solid tumors is the cancer new product development equivalent of the quest for the "Holy Grail."
Interview with Dr Carl June on what the next decade holds for CAR T cells, cell therapy and genome engineering
Interview with Prof John Gribben at second European EHA EBMT CAR T cell therapy meeting in Sitges, Spain
Commentary on Day 2 of the EHA EBMT 2nd European CAR T cell meeting
Commentary on first day of EHA EBMT European CAR T meeting in Sitges, Spain
Can innovative our ability to reinvigorate stalled CAR T cells affected by immune escape from CD19 loss or downregulation of BCMA?
Looking beyond CAR-T cells and checkpoint blockade, there are some promising young companies on the rise to watch out for - here's one of them
A report card on important trial updates across gastric, pancreatic, liver, and colorectal cancers at ASCO GI 2020.
Novel approaches in AML seek to overcome the challenges of the past and improve clinical outcomes.
Highlights and lowlights from Day 1 of JPM20
Following the recent failure of Incyte's itacitinib in acute GVHD, we look at promising early developments following in their wake.
TIM-3 may have a role to play in myeloid hematologic malignancies such as AML and MDS. We explore the scientific rationale, competitive landscape, and initial clinical data.
Six key strategic factors to consider going forward in the quest for future oncology R&D pipelines
A look at what happened from the DREAMM1 to DREAMM2 trials exploring the BCMA ADC belantamab mafadotin in refractory multiple myeloma and why GSK have a challenge ahead
A look at the KEYNOTE-522 and neoTRIP clinical trials in neoadjuvant TNBC
A look at some of the highly ranked clinical data presented over the weekend in Orlando
Science Friday at ASH19 with a look at various lymphoma and myeloma developments
A look at off Broadway abstracts on early new product development and scientific findings of interest
Non-T cell based immunotherapies that could be promising in hematologic malignancies
Some hidden gems and under the radar abstracts that may appeal to the off-Broadway crowd at ASH19
Highlights from SITC 2019 including small cap biotechs with novel or innovative approaches to consider
If we want to improve on the current results with IO therapies then we need to go to basics and understand the biology of each disease subset in the context of what we've learned so far
What's hot at SITC19 this year? We highlight half a dozen key presentations of interest to BSB readers and explain why they matter.
What new things will we learn about the microbiome at SITC19?
There are some potential unexpected new pretenders to the Novartis and Kite's CAR-T cell therapies in Europe. We discuss what they are and why they should be taken seriously.
As checkpoint therapies start moving into early stage disease, how do we go about deciding which people to treat? An example using TNBC.
Highlights from the PROfound trial in advanced prostate cancer and other stories of interest
Key findings and commentary on the third day of ESMO
Review and analysis of key trials presented on the second day at ESMO 2019
Commentary and Insights from Day 1 of ESMO19
Some early stage oncology agents in development that seek to target and tackle inhibitory and immunosuppressive factors
What should we be watching out for in terms of red and green flags at ESMO on the breast cancer IO front?
WCLC 2019 Review – Part 3 - Targeted Therapy Highlights excluding KRASi
Summary of IO highlights and lowlights from WCLC 2019
Is Siglec-15 a key target in overcoming immunosuppression in some cancer patients?
An initial primer on the emerging area of Siglecs within the glycobiology niche
A potential role for epigenetic therapies in straddling the divide between transcription factors and the immune system...
What can we learn from recent trial data exploring a STING agonist in combination with anti-PD-1 in advanced solid tumors including TNBC & melanoma?
Our latest analysis of the ever evolving NSCLC landscape following BMS’s announcement on CheckMate-227
Thoughts and commentary on the Jounce-Celgene collaboration update and the emerging ICOS landscape
A review of our Top 10 sarcoma results from ASCO19 plus commentary from a specialist KOL in this niche
Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?
Insights on the updated phase 1b clinical data evaluating Neon's personalized vaccine NEO-PV-01 in combination with nivolumab in advanced cancers?
What can we learn from the recent data presented on Affimed's innate bispecific platform? A candid conversation with CEO, Dr Adi Hoess
Next generation IO molecules are likely to feature bispecific antibodies - can we address the weaknesses seen with immune agonist antibodies by switching modalities?
We saw a number of challenges emerge with immune agonists as antibodies and now companies are experimenting with them in bispecifics - what needs to be considered to make them work? What will the next wave of IO look like?
Can mRNA disrupt cancer therapy and boost responses beyond what we see with checkpoint therapy?
Is T cell therapy like Game of Thrones?
What can we learn from biomarkers and immune profiling in patients receiving bempeg, a CD122-directed pegylated IL-2 therapy
How is Synthorx's IL-2 cytokine THOR-707 different from other compounds in this niche?
How the design of different cancer approaches can affect clinical performance
Round-up and analysis of key lymphoma data at iCML 2019
Can we employ red blood cells in allogeneic, off-the-shelf cellular therapy products for the treatment of cancer?
New data suggests there may be value in targeting CD73 as well as the A2A receptor in certain tumour types...
Looking under the hood to find biomarkers of response and outcomes, ,
On KRAS in lung cancer, HRD in pancreatic cancer (not POLO) and genomics in RCC
A look at some of the hidden gems and struggling compounds in competitive niches at ASCO19
Insights from Day 2 of ASCO19, plus a look at what to expect in the plenary and other sessions today.
A review of some this key data presented including new compounds in early development and how they stack up against existing therapies.
Hidden gems - what to watch out for at ASCO19 off the beaten track amongst the wealth of data to peruse
A review of 7 different targets and 18 different compounds in the maturing and highly competitive bispecific niche.
Highlights (and lowlights) from Day 2 of immunotherapy presentations at CIMT 2019 in Mainz.
A report from the CIMT 2019 annual meeting exploring key highlights from the presentations on tumour biology and cancer immunotherapy.
Working out which are markers versus valid targets is going to be key in IO progress. Here we look at one particular candidate...
How next generation immunotoxin approaches can overcome capillary leak syndrome and be effective anti-cancer agents
Exploring the many challenges associated with targeting KRASG12C and why we should temper enthusiasm for this niche
A review of the latest available TLR data and a look at an emerging biotech Silverback Therapeutics in this niche
Gritstone have evolved from start-up biotech to clinical stage oncology company. We catch up with them and discuss their latest progress.
Can gamma delta T cells be effective as a therapeutic in GBM?
Is there a better way to target myeloma than with BCMA alone? Data suggests there's plenty of room for improvement.
A look a the updated adenosine pathway landscape and how it is progressing
As look at ways of targeting 𝞬𝝳 T cells, we may need to consider whether or not the situation is immunosuppressive or proliferative
Neutrophils may be responsible for inducing immunosuppression and resistance to checkpoint therapies so how do we target them in the clinic?
With the help of a leading pathologist, we examine the challenges associated with PD-L1 and TMB as biomarkers for patient selection
Having a companion diagnostic is important for precision medicine, but can they accurately predict who is most likely to respond to cancer immunotherapy?
Mobbed posters indicate attendee interest, but is it justified?
A look at Apexigen's anti-CD40 data in advanced pancreatic cancer - hit or miss?
What are the emerging trends from AACR19? What can we expect to see emerge over the next year?
In the second part of our review of the AACR19 cancer immunotherapy program, we take a look at more noteworthy sessions in Atlanta.
First part of a look at the immune-oncology track at AACR19 - there's a LOT going on this year!
Do we need to target Tregs in order to get more anti-cancer efficacy with immunotherapy? We take a look at what we've learnt about this niche.
Update on T cell bispecifics and other key topics in early stage IO development
A snapshot of 3 UK cell therapy companies, Autolus, Achilles and GammaDelta Therapeutics
Figuring out how to combine different IO approaches will take time so what have we learned lately?
TC BioPharm are a cell therapy company to watch out for as they look towards an IPO in 2020
What can we learn about gamma delta T cell cancer immunotherapy in China?
A look at the γδ T cell competitive landscape with cell therapies, antibodies and bispecifics in early stage development
Can we make novel allogeneic cell therapies with γδ T cells? We find out!
Can γδ T cells be employed as a therapeutic against cancer?
Targeting STING in cancer with a systemic small molecule approach? What's the story?
What does a next generation STING agonist look like and what issues is it attempting to address?
An in-depth look at the growing STING R&D landscape in oncology
What's hot in renal cancers? We take a look at what to expect at ASCO GU19 and offer insights on the emerging data
What can we learn from the key trials being presented at ASCO GU19 in San Francisco?
Should you read a book on the History of Cancer Immunotherapy? Here's our review...
An upcoming small biotech focused on IO targets with their novel platform approach
What to watch out for at the ASCO GI19 conference in San Francisco
Going beyond anti-PD1 checkpoint blockade is important if we want to help more people respond to cancer immunotherapy
Commentary on some up and coming biotechs in the oncology space
Insights and commentary from the second day at #JPM19
Insights and commentary from the first day of JPM19
Beyond T and NK cells, other immune cells can be used for cell therapies in solid tumours
FDA slaps a partial clinical hold for unwanted side effects, now what?
How do we improve CAR-T cell therapy in CLL? A look at clinical data plus a new thought leader interview in the space.
A rock around the breast cancer clock with cancer immunotherapies and targeted agents from SABCS18
Review of a round dozen key abstracts at #ASH18, both scientific and clinical data is under the microscope!
Highlights from the AACR special conference on tumour immunology and immunotherapy
From one BCMA directed CAR in 2015, we now have a very competitive niche in multiple myeloma. What's in store?
There are a number of important lessons we can learn from early phase 1 trials. Here are some of them.
AstraZeneca miss on OS in the phase 3 MYSTIC trial – what next? At one point we were posting…
What is old is new again - a look at some forgotten oncology targets that are coming back in fashion
Update on PIVOT-02 with nivolumab plus NKTR-214 in 1L metastatic melanoma
The evolving story of how commensal microbiota can affect response to cancer immunotherapy
Latest news and insights on immune escape mechanisms associated with cancer immunotherapy
Can we improve on the tolerability of the nivolumab-ipilimumab regimen by designing better a checkpoint inhibitor?
An extensive round-up of what to expect from SITC18 ahead of the abstract reveal
A top-line review of the ASH18 abstract palooza
Achilles Therapeutics is an emerging biotech in the cell therapy space that is based on truncal neoantigens
Initial results from the neon NEO-PV-01 phase 1B trial presented by Dr Patrick Ott
With new data on the blood-based TMB test at ESMO, what can we learn about this approach?
New trends in early drug develoment and Developmental Therapeutics
Highlights from Day 1 of #ESMO18 in Munich
Can we use technology to squeeze more out of B cells to generate an army of killer T cells?
The changing face of renal cell cancer from several perspectives
Wins for Pharma, some shakeouts for small biotechs on manic Monday at #ESMO18
Highlights and lowlights from Munich
Highlights and lowlights from Day 2 of #ESMO18
A look at the CheckMate-331 and CheckMate-451 study and other SCLC trials
A dozen poster abstracts to watch out for at ESMO18 on a wide range of topics...
Third ESMO18 preview on oral abstract presentations
A look a progress on NeoVax in GBM, RNA vaccines and even a novel CAR T cell therapy with a difference.
Some key notes on CAR T cell therapy developments ahead of SITC18 and ASH18
Highlights from the first day of #CICON18 in New York
ESMO18 Preview 1 - Late Breaking Abstracts to watch out for
After the WCLC2018 preview, what does the data actually teach us? A round up and commentary on 16 key trials
Our second preview of what to expect at CICON18 - top 10 poster abstracts
Part 1 of our #CICON18 Previews - a look at 11 intriguing IO related studies
Cell therapy is a very broad church - here's an interesting approach to keep an eye on
Update on BCMA, SLAMF7 and other targets in multiple myeloma
What to watch out for at WCLC2018 in Toronto later this month
Four areas of research in oncology R&D that may involve new targets or new indications emerging
Will NK cell engagers have a positive impact on checkpoint therapy and other adaptive immunotherapies?
Lessons learned from recent failure and a look at where a few new developments might be coming from...
On launched products, armored CARs and the potential threat from China
On targeting immunosuppression and some obscure oncogenic targets
Are the PARPi a class effect or are there real differences between them that may become more apparent in future combo studies?
Five key recent papers that are well worth looking at and what the science teaches us about next directions
Beyond PD-1 and CTLA4 there are other checkpoint and IO targets being investigated. We take a look at one of the promising ones...
An in-depth look at Adaptimmune's TCR T cell therapy program
Rumination, notes and updates on CAR-T cell therapy, checkpoint blockade, SCLC, genomics and TCR signalling...
One of the ongoing challenges with cancer immunotherapy is monitoring response to treatment. Even if you…
Bringing together disparate notes on cytokines and how they can be useful as an immunotherapy partner.
The latest part in our cytokine mini-series explores the potential for incorporating them in CARs or combining with checkpoint blockade through the lens of an expert in the field...
What can we learn from the updated Nektar NKTR-214 data presented at #ASCO18?
Update on TLR9 as a target and what we learn from the latest clinical data
Thoughts, reflections and learnings from the recent phase 3 lung cancer readouts from a lung cancer specialist...
Ongoing discussion and debate about data in lung cancer and up and coming innate immunotherapies that may move the needle in IO-IO combos.
Dr Gilberto Lopes discusses the KEYNOTE 042 and 189 trials in first-line non-small cell lung cancer (NSCLC).
The promise and pitfalls of Day 1 of #ASCO18
We explore the importance of looking under the hood at various expression levels...
Not all IO-IO combos will be successful in solid tumours, what can we learn from the Genmab-Janssen news for daratumumab in NSCLC?
It’s a Bank Holiday weekend on both sides of the pond, which is always a good excuse for some…
Can TMB replace PD-L1 as a predictive biomarker of response for immune checkpoint blockade therapy?
A preview of key abstracts in urothelial and bladder cancer expected to be presented at ASCO18
What do we learn from the ASCO abstract release? Quite a lot! Here we debunk some of the controversial issues and inaccuracies that have arisen
Key themes and topics of interest in the poster halls - what stands out amongst several thousand posters?
What to watch out for at ASCO18 in the oral presentation sessions
A look at the history of CAR T cell therapy design and where things are headed in the future with one of the original cell therapy pioneers
A look at path to market strategies open to a small biotech in the CAR-T cell space
How do we drive more T cells into the tumour? Here's one company who are looking to do just that.
Going beyond PD-1, PD-L1 and CTLA-4 to explore other inhibitory checkpoint targets that may be useful in the clinic
A look at various lessons from recent IO trials and how they can applied to new readouts expected at ASCO18
A look at how basic and translational evidence points towards TGFβ as a possible new target for IO combos in some tumour types
A look at one way with which we can target the tumour microenviroment to improve response of cancer immunotherapy
What can we learn from the TRACERx studies in lung and renal cancers? Quite a lot, it seems...
4 KOLs tell us what they really thought about the 3 studies in 1L NSCLC presented at AACR18
A look at TMB as an emerging biomarker for cancer immunotherapy - is it ready for prime time?
Answering questions on the 1L NSCLC data presented at #AACR18
A look at the latest 1L NSCLC trial readouts
A look at the Class of 2018 new products in development - a hit or miss?
A look at some new - and very early - directions in CAR T cell therapies, especially in solid tumours.
How can we improve on monotherapy with PARP inhibitors?
How do we address primary and acquired resistance?
Will the results from Merck's KEYNOTE-042 study change practice in 1L NSCLC?
Beyond the news that Incyte and Merck's epacadostat plus pembrolizumab combo failed to hit its endpoints in advanced melanoma, what other IO-IO combos should we turn to?
A look at an emerging IO target that might be useful in ceratin tumour types and patient subsets when given in combination
What's hot at #AACR18 in terms of data to watch out for in a certain tumour type?
A look at the clinical features that predict for early discontinuation with checkpoint blockade in ovarian cancer
An in-depth look at the French biotech company Innate Pharma and where they are now two years on from our last look at their IO pipeline.
What can we learn from the early data exploring PARPi plus checkpoint blockade combinations in ovarian cancer?
A post mortem of the Rova-T TRINITY trial and a look to the future in SCLC
A look at the key lung cancer data expected at AACR18 and what to expect from the latest squamous NSCLC
A look at what Gamida Cell, an up and coming cellular and innate immunotherapy company are up to...
A look at targeting NK cells with immune agonists, cytokines and adoptive cell therapies
A look at the history of NK cell development and where we're going in future with this IO approach
Our latest primer explores NK cells and their role in oncology R&D - it's an up and coming area
Some key highlights from the recent inaugural pancreatic cancer symposium in Houston
A look at an emerging area for biomarkers and stealth cancer therapeutics
A look at some of the issues underlying IO-IO combos and whether they can help us assess if these trials will succeed - or not.
In this post, we take a look at new clinical and scientific findings that may pave the way forward for the future in the CAR T cell space
What did Dr Grupp and Dr Komanduri learn from participation in the CAR T cell therapy trials?
A look at innate approaches to stimulating the immune system including IL-15 agonists
Insights from researchers in the CD47 niche - what do they really think?
A look at the players in controversial CD47-SIRPα landscape
A look at the changing face of the RCC landscape, including current and near term trial readouts
As inconsistent data abounds, is it time to move on from PD-L1 as a biomarker of response to checkpoint blockade?
A look at some new targeted and IO combinations in development for advanced prostate cancer
A look at biology behind targeting CD47 in cancer and some of the controversies plaguing the space
Highlights and Lowlights from ASCO GU 2018 - what to watch out for.
BMS announced that CM-227 hit PFS in lung cancer patients with high tumour mutation load, now what?
A look at Dr Malcolm Brenner's work on virus specific T cell therapies
FDA places Bellicum's BPX-501 on clinical hold - what's the story and what's next?
At ASCO-SITC this weekend there was some compelling new scientific data highlighting subsets of patients who might be eligible for cancer immunotherapy, including novel combination approaches.
Expert interview with Dr Glen Barber reignites the controversy over whether STING agonists could cause metastasis in cancer patients.
A look at where we are in pancreatic cancer and how the landscape has evolved of late...
A look at the pipeline of the up and coming Seattle biotech, Alpine Immune Sciences
Can STING agonists promote cancer metastasis in some patients? That's one of the key questions from new research linking chromosomal instability with tumor metastasis through activation of the cGAS-STING pathway.
A look at 8 key abstracts being presented at #GI18 in San Francisco this week.
How does positive trials from Roche and Merck impact the 1L NSCLC landscape?
A look at how new approaches in synthetic biology could revolutionise cell therapy in solid tumours
Commentary on Day 3 at 2018 JP Morgan Healthcare Conference in San Francisco
Commentary on Day 2 of the 2018 JP Morgan Healthcare Conference in San Francisco
Commentary on Day 1 of the 2018 JP Morgan Healthcare Conference in San Francisco
New series on Key Trends in Oncology for 2018
New approaches that enter a market unexpectedly can disrupt the status quo and push out more severe therapies to later lines of treatment
A look at key pipeline developments in multiple myeloma through the lens of a global expert in the field
An interview with Dr John Leonard exploring his thoughts on some of the key lymphoma data at #ASH17
As we see new readouts emerge with different doublets and triplets in CLL, how will they impact the treatment landscape?
Commentary on Sunday at 2017 ASH annual meeting in Atlanta
A look at some of the sessions and learnings from the first day at ASH 2017
People love hearing about new or emerging cancer targets - there's always the hope that one might find something cool that could move the needle and really make a difference...
The first phase 3 trial in 1L NSCLC to hit the PFS endpoint is Genentech's IMpower150. What can we learn from this study?
A look at the latest CDK4/6 inhibitor data including the important phase 3 trial with ribociclib (MONALEESA-7).
A look at what's hot in CAR T cell therapies at #ASH17
The Mav's key oral abstracts to follow at #ASH17 -- warning this list includes quirky selections!
A look at a selection of promising Developmental Therapeutics abstracts from ASH17 - what's in store this year?
A look at loss of heterozygosity and what it means for new lung cancer therapies
Integrated biomarker approaches are beginning to emerge to help researchers segment patients better for appropriate therapy. Here's one approach...
A look at the cabiralizumab plus nivolumab combination in PDAC at SITC over the weekend
A look st Syndax's entinostat and what happens when given in combination with pembrolizumab in melanoma and lung cancer
A look at Nektar's promising IO portfolio and what's next for the up and coming biotech
Ten stars from the clinical presentations on Day 2 of SITC 2017
A CAR T cell therapist's perspective on the Juno JCAR015 ROCKET dataset
A look at some of the main events from the first day at SITC 2017 - including Juno's ROCKET data.
Final SITC17 Preview and a look at key talks now that the abstracts are available.
A look at new targets, molecules and approaches to cancer research from #TARGETS17 in Philly
Science Fridays: A look at six key studies recently published on cancer research that BSB readers can learn from.
Highlights from Day 3 of the AACR-NCI-EORTC Molecular Targets meeting in Philadelphia
A look at some of the important data coming out of Day 2 of #Targets17 in Philadelphia
Commentary on Day 1 of 2017 AACR NCI EORTC Molecular Targets and Cancer Therapeutics Conference in Philadelphia
A look at ROVA-T's chances in the upcoming phase 2 TRINITY trial readout
A look at the SCLC landscape including some promising new developments
A look at the trials and tribulations for Immune Design's CMB305 and what's the latest in 1L NSCLC
What other approaches might be useful for predicting response (or non-response) to cancer immunotherapies?
With increasing evidence that CD123 is a suboptimal target in AML, what other approaches might be more useful to consider?
A look at some of the LBA posters to be presented at #SITC17 in November
A look at 5 key oral late breakers at #SITC17 and what to expect or watch out for
Can we address inhibitory factors that dampen NK cells to enhance the anti-cancer effect on tumours?
Our latest predictions in 1L NSCLC and what to expect from the upcoming trial readouts in this niche
A look at what's different about exceptional responders in PDAC and what can we learn about neoantigen approaches here?
A look at the latest developments in cancer immunotherapy in ovarian cancer, with a particular focus on neoepitopes and cancer vaccines.
A look at Ugur Sahin's BioNTech and personalized mRNA vaccines
Genentech have several cancer vaccine collaborations in place, where do they see the future going in this niche?
Part 1 of a new mini-series on cancer vaccines. This one covers an update on Neon's neoantigen approach...
After pseudoprogression, the IO field has moved onto hyperprogression. What is it and why does it matter?
Is the CAR T cell therapy space ready for disruption? At least one researcher thinks so. What does this entail?
A post mortem analysis of the Bavarian Nordic PROSTVAC cancer vaccine trial failure in CRPC
An early look at a new IO combination that may help overcome resistance to checkpoint therapy
A look at the last day of ESMO17 with key data on cancer vaccines, checkpoint and targeted therapies to explore
A roundup of the key trials and targets presented on Sunday at #ESMO17
A look at mostly lung cancer highlights from the first 2 days at #ESMO17
A look at some of the small biotechs and what they're developing on IO front that looks intriguing at #ESMO17
8 key ImmunoOnc studies being presented at #ESMO17 this month
A look at what's happening with Cellectis and their clinical trial program with CD19 and CD123 CARs.
What does the future hold for Cellectis and allogeneic "off the shelf" CAR T cell therapy?
Gene editing looks set to become entrenched in allogeneic CAR T cell development, so what's new?
Does timing and sequencing of immune agonists impact their effect when given with checkpoint blockade?
A look at the changing HCC market and how pipeline agents may (or may not) impact the landscape...
After recent readouts of breast cancer trials at #ASCO17, where do we go next for future combos? Based on recent preclinical research, we have some ideas...
A look at the interim results from the BMS CheckMate-214 trial in renal cell carcinoma
Top 5 IO oral abstracts to watch out for in Madrid
A look at various factors that can influence cancer immunotherapy trials through the lens of an immunologist
A look at the role of pre-existing immunity in cancer immunotherapy trial readouts at ASCO17
Jumpstarting the immune system with a synthetic immunity approach - how can we do this?
How can we boost the efficacy of checkpoint therapies? One way is to drive more activated T cells into the tumour.
A look at AZN's miss with their IO-IO combination in 1L NSCLC
A look at why checkpoint therapy trials might be giving us inconsistent results of late
Update on Nektar Therapeutics IO portfolio and a look at their burgeoning autoimmune disorder pipeline
A look at the intersection of epigenetics and cancer immunotherapy - what can we learn and where are we going in this niche?
A second look at the evolving 1L NSCLC landscape with a focus on MYSTIC and IMpower150
Commentary on 2017 Paris Immuno-Oncology summit organised by European Academy of Tumor Immunology and Miltenyi Biotec
Why did the IMvigor211 phase 3 trial with atezolizumab in UBC fail? BSB spoke to Prof Tom Powles.
What can we learn from the Immune Design data in sarcomas with their NY-ESO-1 vaccine?
What's new in the sarcoma space? Which novel approaches are worth watching out for?
Overcoming resistance to monotherapy treatment with checkpoint blockade is crucial for success with IO combos. Here's one potential solution...
A look at checkpoint blockade in early stage breast cancer - encouraging or not?
A look at the initial results from the Novartis CTL019 pivotal trial in aggressive lymphoma (JULIET).
Beyond the incremental improvements seen in clinical trials, what are the new trends emerging from ASCO 2017 that will impact oncology R&D?
Some intriguing surprises in the CAR T cell therapy abstracts this year...
A look at an up and coming niche in cancer research that may turn out to be useful in conjunction with checkpoint blockade
A look at 5 key abstracts that tickled my fancy from #ASCO17; Warning - not all are positive!
Update on #ASCO17 data for IDO1 inhibitors in various cancers
A fireside chat with a leading KOL involved in cancer research on resistance.
Durvalumab grabs pole position in unresectable NSCLC amongst IO compounds
We've been overdue a correction in the irrational exuberance around IO... is this the tip of the iceberg?
A look at a promising biotech in the neoantigen space - what's their approach and how might it fare?
With 'liquid biopsies' on the rise, we take a look at another potential candidate that could be useful - exploring exosomes.
A candid look at new approaches being explored in cold tumours using prostate cancer as an example
Through the keyhole with a look at AZN and MedImmune's IO portfolio
Expert interview at AACR17 with Dr Julie Brahmer on lung cancer immunotherapy resistance and preview of ASCO17 abstracts
Encouraging new developments in GBM with a novel CAR T cell therapy
How do we overcome resistance to cancer immunotherapies? Here, we have an in-depth interview with a thought leader in this space.
Dr Daniel Chen from Roche/Genentech shares his vision for the future of cancer immunotherapy at AACR17.
Five emerging cancer research trends we picked up at AACR17 that you should be aware of.
Interview with Professor Peter Schmid, Barts Cancer Institute.
Commentary on Tuesday at 2017 AACR annual meeting in Washington DC.
Commentary on Monday at the 2017 AACR annual meeting.
Commentary on Sunday at the 2017 AACR annual meeting
Highlights from Day 1 at AACR17
A look at some of the key sessions featuring checkpoint blockade at the AACR 2017 annual meeting
A comprehensive review of the key abstracts in the CAR T cell therapy niche and hints of the latest emerging trends
A look at a new area of immune-oncology that looks set to be in the consciousness more over the next few years
Overcoming immune suppression in the tumour microenvironment
A look at some recent clinical data and what we can learn from the new data expected at AACR in DC
The first of our strategic and thematic AACR Previews for the 2017 annual meeting is here
After a rocky 2016, what does 2017 hold for Juno as they switch focus from JCAR015 to JCAR017?
A look at another surprising factor that might affect efficacy of cancer immunotherapy and checkpoint blockade.
After JAK1/2 upregulation and PTEN loss, a third mechanism of resistance to checkpoint blockade has been identified. We discuss the issues around this latest challenge...
Insight from BMT Tandem 2017 meeting into latest Cell Therapy data
A look at cancer immunity and the new framework for exploring the cancer-immune setpoint.
A look at another approach for turning cold into hot (or warmer) tumours with cancer vaccines.
What we learnt at ASH16 on how to better target the tumour microenvironment in lymphoid malignancies.
Exploring clinical trials with targeted therapies, including PARP and ATR inhibitors and combination approaches
A draft manifesto for IO in cancer research and what we need to learn
A look at gems from the #GI17 poster halls or molecules destined for Dog Drug Heaven?
A couple of trials at ASCO #GI17 look promising in terms of trial design with encouraging implications for the future in metastatic colorectal cancer.
Will gastric cancer be one of the next indications for nivolumab?
SABCS16 expert interview on the potential of circulating tumor DNA to change the treatment of cancer.
A look at the how several major phase 3 trial readouts will affect the 1L NSCLC landscape
Update on Neon Tx as they move into commercial new product development with their neoantigen platform.
Second in our series of expert interviews from the 2016 San Antonio Breast Cancer Symposium features Dr Leisha Emens
Commentary on Wednesday at JPM17 in San Francisco
Commentary on Day 2 of the 2017 JP Morgan Healthcare Conference in San Francisco
Commentary around some of the corporate presentations at Day 1 of the 2017 JP Morgan Healthcare conference in San Francisco.
Interview with Dr Stephan Grupp on the data he presented at ASH16 and what the future may hold for CAR T cell therapy in pediatric ALL
A look at the emerging trends we can expect in 2017 for cancer research
#LeonardList showcases 10 Lymphoma Abstracts at ASH16
We answer more questions on CAR T cell therapies and ADCs in acute leukemias from ASH
3 trends from SABCS16 that you may hear more about
A look at the new various developments in CAR Therapies targeting BCMA in multiple myeloma
We answer several critical questions that readers have sent in based on the CAR T cell data at ASH this week.
Highlights (Part 1) from 2016 ASH Annual Meeting in San Diego - 7 initial impressions
Highlights from the Charles River Immunotherapy Symposium in Munich, 2016
If you have plans to be in San Diego for #ASH16 what should you attend on Friday?
A most unfortunate follow-up to the ongoing safety issues with Juno's JCAR015 and neurotoxicity in the run-up to #ASH16
Without effector T cells in the tumour, checkpoints won't work. So how do we attract more in? Here's one way to do it...
A look at new ways to boost checkpoint therapy performance including agents in development from small biotechs
Update on important new data in urothelial cancers and how the landscape is moving quickly
Does adding lirilumab to nivolumab move the needle in relapsed SCCHN?
An in-depth review of what to expect from AML new product development in San Diego
What To Watch Out For in CAR T Cell Therapies at ASH in San Diego in December 2016
Initial impressions of abstracts for ASH16 in San Diego
Four more combination trials of interest in cancer research that may be worth watching out for
Four pretty cool approaches to combination cancer immunotherapy stood out at #ESMO16 in Copenhagen...
How will glycomics impact cancer research? Some interesting new developments are emerging in this field
Can biomarkers help us improve clinical trial outcomes?
Yesterday saw the FDA approval of atezolizumab (Tecentriq) for the second-line treatment of metastatic…
Commentary on Sunday at ESMO16 with a focus on the lung cancer data in the Presidential Symposium
Commentary on Day 1 at ESMO 2016 Congress in Copenhagen.
Audio Slideshow tour of HalioDx lab that shows how digital pathology is used to calculate Immunoscore an immune based colon cancer assay
Corvus Pharmaceuticals accelerates development of A2A receptor antagonist CPI-444 that could improve checkpoint responses.
Interview with Dr Eric Pamer on impact of the microbiota on the innate and adaptive immune systems and future directions.
New research shows potential of cell therapy with allogeneic memory-like natural killer NK cells in AML.
Interview with Prof Ton Schumacher at scientific meeting to celebrate 40 years of Centre d’Immunologie de Marseille-Luminy (CIML).
Interview with Professor François Romagné, Scientific Director of MI-mAbs, an immuno-oncology drug discovery venture in the Marseille Immunopôle cluster.
Interview with Innate Pharma CEO Dr Hervé Brailly on clinical trial readouts expected and his vision for company
Professor Eric Vivier is Director of the Centre d’Immunologie de Marseille-Luminy and a co-founder of Innate Pharma and the Marseille Immunopôle. He is a leading researcher in the field of innate immunity.
Interview with HalioDx CEO Vincent Fert on commercial strategy for Immunoscore diagnostic test.
A look at 9 key abstracts in ovarian cancer at #ESMO16 and what to expect
What can we expect in Head & Neck cancer at #ESMO16 in Copenhagen?
A look at what to expect from the lung cancer late breakers at #ESMO16 - are there any surprises or controversies?
Launch of the BSB Journal Club - this inaugural edition explores T cell dysfunction and exhaustion
Interview with Prof Fran Balkwill from Barts Cancer Institute on 3D modelling of the tumor microenvironment in ovarian cancer
Part 2 of interview with PsiOxus Therapeutics CEO Dr John Beadle discusses corporate strategy and challenges faced by an emerging biotech company.
An innovative and promising approach to cancer immunotherapy using adenoviruses to deliver multiple warheads to tumours
A primer on the oncolytics viral therapy landscape - beyond T-VEC
This is the second in our mini-series on neoantigens and looks at whether neoantigen based cancer vaccines can make a difference in the treatment of solid tumors.
Cary Pfeffer of Third Rock Ventures describes how a novel neoantigen vaccine in academia transitioned into a commercial company with exciting prospects...
A primer on neoantigens and their importance in cancer research
The BMS CheckMate-026 trial in 1L NSCLC did not meet it's primary endpoint. What can we learn from the failure?
Collaborations in the adoptive cell therapy space have now branched out from autologous to allogeneic products. What's the skinny?
What factors contribute to resistance with checkpoint blockade and how can this be overcome?
July Reader Q&A - thoughts on Jounce, Celgene, BMS, J&J and CAR T cell therapies...
A example of how different targeted therapy and immunotherapy combinations could be both useful and different from what we've seen before
Juno ROCKET trial put on clinical hold following 3 death due to cerebral edema. What's the skinny?
Will priming the tumour microenvironment with epigenetic therapies such as HDACs lead to enhanced activity with subsequent immunotherapy?
With so many new anti-cancer agents, including immunotherapies, emerging in company pipelines, this means that we could see the evolution of important therapy sequences... going beyond combinations.
The oncology bispecific market is heating up with J&J collaborating with Macrogenics and Novartis with Xencor. We discuss the skinny...
We've seen some wonderful responses with checkpoint blockade and cancer immunotherapies, but there are some downsides that need to be considered.
Can we turn a cold tumour into a hot one where some patients can respond to therapy?
Update on ASCO checkpoint blockade data for colorectal and other MSI-High cancers
An easy to use new biomarker emerges to help oncologists select colon cancer patients for cancer immunotherapies.
Gene editing is coming to the US CAR T cell space - what's happening and what will the impact be?
Can we find and use several biomarkers to triangulate responders and non-responders?
A look at the increasingly competitive metastatic urothelial carcinoma landscape
What to make of the various combination trials presented at ASCO 2016?
A number of points of strategic importance fell out of the ASCO data dump. What are they and why do they matter?
Commentary from Monday at ASCO 2016 American Society of Clinical Oncology annual meeting in Chicago
Prior to chemotherapy men with advanced prostate cancer did not live longer if they received ipilimumab compared to just receiving placebo. The phase 3 trial was a failure.
Top-line commentary from Sunday at ASCO 2016 annual meeting.
Top-line commentary from Saturday at ASCO 2016 annual meeting.
Can we safely combine a STING agonist with a checkpoint inhibitor to generate more effectiveness in melanoma and lymphomas?
We asked experts at AACR what they really thought...
What can we learn about clinical trial design from immunotherapy combinations?
Commentary from the AACR Precision Medicine Conference in Miami on Targeting the Vulnerabilities of Cancer.
How can we improve T cell trafficking in ovarian cancer? Professor Coukos highlights numerous ways this could be achieved!
A look at the BCMA/APRIL landscape in multiple myeloma - this is rapidly becoming a competitive target
Beyond checkpoint blockade, companies are now exploring what happens when you combine them with immune agonists such as OX40. Here we explore an industry perspective.
A wide ranging discussion about how to light the fires in non-immunogenic or cold tumours - OX40, STING, vaccines and more discussed!
Can we safely and effectively add a checkpoint inhibitor to standard chemotherapy and VEGF inhibition?
Early proof of concept in patients with metastatic colorectal cancer.
At the recent AACR meeting, Dr Michel Sadelain gave a presentation on turbocharged CAR T cells, and shared some of his ideas on how to move the field forward.
Chemotherapy can have a potentiating effect on cancer immunotherapy. The positive effects may surprise some readers...
What were the major learning points from AACR that will make an impact over the next 1-2 years? Chhhhanges are afoot...
Season 2 of the Novel Targets has launched, plus the eagerly awaited April Readers Q&A Mailbag
Commentary on Tuesday sessions at AACR 2016 annual meeting
Commentary on Monday at AACR 2016 annual meeting
Commentary from Sunday at 2016 AACR annual meeting
Commentary on Day 1 of AACR 2016 annual meeting in New Orleans.
First-line data for AstraZeneca’s ($AZN) third generation EGFR inhibitor osimertinib (Tagrisso) impresses at the 2016 European Lung Cancer Conference in Geneva.
In this preview of AACR 2016, we're looking at the CD40 landscape, some of the new companies that have entered the scene and what presentations to look out for at AACR 2016 (and why they matter).
Today post is on OX40 (CD134) as a novel immuno-target and what the OX40 cancer immunotherapy landscape looks like.
There are now several agonist antibodies in development and entering the clinic that seek to activate GITR, and new data is expected at AACR 2016.
This post looks at some of the data at AACR 2016 for cancer immunotherapies that target IDO1 and TDO and their downstream effectors.
A look at alternative checkpoint inhibitors, anti-TIM-3 and LAG-3 compounds in early development at AACR
In this post I've taken a close look at one cancer immunotherapy approach with a lot of data at AACR - bispecific T cell engagers.
Commentary on some of the latest cancer immunotherapy papers
Pick of 10 abstracts at AACR 2016 annual meeting in New Orleans that may answer critical cancer research questions
Cancer Immunotherapy dominates AACR 2016 annual meeting in New Orleans.
Review of 4 noteworthy posters at the 2016 European Breast Cancer Conference in Amsterdam organised by European Cancer Organisation ECCO
Trends in Haplo stem cell transplants may impact Bellicum Pharmaceuticals adjunct T Cell therapy BPX–501
Could immune resistance be reversed or prevented by the addition of appropriate checkpoint blockade? Which ones matter though, that is the critical question?
Interview at BMT Tandem 2016 about a novel cell therapy that could compete with or replace CAR T cell therapy
Commentary on presentation by Dr Philippe Armand at BMT Tandem meeting on “Checkpoint Blockade in SCT, Data & Hope, Promise & Peril”
Interview with Dr Michael Jensen on CD19 CAR T Cell Therapy
Interview at BMT Tandem 2016 with Dr David Porter U Penn on CD19 targeted CAR T cell therapy in CLL
Preview of noteworthy sessions at 2016 BMT Tandem meeting in Honolulu, Hawaii
How do we decide how to incorporate the newly approved drugs in Multiple Myeloma and what's the next wave of therapies we can expect to see evolve?
What are some of the strategic trends and drivers in the Graft versus Host Disease (GvHD) space at #BMTTandem16?
Unum have developed a completely different approach to traditional CAR T cell therapies. Will they make an impact in patients?
A novel cell therapy approach uses T cells targeting multiple tumor-associated antigens.
Who will move the needle in gastric and oesophageal cancers - targeted therapies or checkpoint immunoherapies?
Will checkpoint blockade be effective in multiple GI cancers and if so, why?
A trial of gemcitabine plus cisplatin plus ipilimumab in patients with metastatic urothelial cancer failed to meet it's primary endpoint.
Commentary on Wednesday corporate presentations at 2016 JP Morgan Healthcare conference in San Francisco
Commentary on some of the presentations at Day 2 of JP Morgan Healthcare conference in San Francisco.
Commentary around some of the corporate presentations at Day 1 of the 2016 JP Morgan Healthcare conference in San Francisco.
ASH 2015 interview with Dr Ian Flinn, Director of the Blood Cancer Research Program at the Sarah Cannon Research Institute.
Part 2 of ASH 2015 interview with Prof Waseem Qasim (GOSH) on the first in man gene edited allogeneic CAR T cell therapy.
Part 1 of an interview with Prof Waseem Qasim.
Adding chemotherapy or an ADC boosts the immunogenic effects prior to checkpoint therapy in metastatic breast cancers
Commentary on Plenary Sunday at the 2015 ASH annual meeting in Orlando.
Commentary on Saturday at ASH15
Where is the field of immune biomarkers going beyond PD-L1 in the next few years?
Checkpoints in classical Hodgkins Lymphoma - how is the data holding up one year on?
At the recent Society for Immunotherapy of Cancer (SITC) annual meeting, Dr Chris Heery presented a poster on the results of a phase 1 clinical trial to evaluate the safety and tolerability of a therapeutic vaccine targeting brachyury.
Our latest Q&A based on reader questions - In the Hot Spot: On CAR T cell therapies
Interview with Dr Mario Sznol on Novel Immunotherapies and Combinations
Dr Tom Gajewski (University of Chicago) talks about work from his lab that shows the gut microbiota can impact the efficacy of checkpoint inhibitors.
Interview with a leading expert on strategies to overcome CAR T Cell Therapy Resistance
At SITC 2015, we heard a tremendous amount of data, but a fresh controversy emerged regarding checkpoint inhibition...
Expert opinion on First Clinical Application of TALEN Engineered Universal CAR19 T Cells in B-ALL
Enoblituzumab is an immune stimulant that targets B7-H3 leading to more T cells.
Is Incyte's epacadostat (IDO1 inhibitor) ready for prime time?
Review of the highlights from the SITC 2015 pre-meeting workshops
Most of the abstracts for the 2015 annual meeting of the American Society of Hematology (ASH) have just gone online.
This is a quick initial preview of a few that caught my attention in the immunotherapy space.
Commentary on the International Cancer Immunotherapy Symposium held at SITC 2015
Preview of what's hot at the 2015 Society for Immunotherapy of Cancer (SITC) annual meeting at National Harbor, MD.
Companies in the ImmunoOncology space are looking at ways to improve responses with checkpoint inhibitors. Adding an immune agonist is one way to do this.
A primer on immunocytokines in cancer immunotherapy with a focus on Roche's CEA-IL2v as a example.
Interview with Dr Jérôme Galon on Immunosurveillance, Immunoscore and Personalized Cancer Immunotherapy.
Preview of the key topics coming up at the AACR-NCI-EORTC Molecular Targets meeting in Boston, including Pasi Janne's interesting data on T790M negative NSCLC...
Should we be using the PDL1 antibody assay to screen patients for therapy with anti-PD1 and PD-L1 checkpoint inhibitors or? How useful is the test?
The debate is heating up!
Radiation has the potential to generate an immune response that may lead to an abscopal effect when combined with a checkpoint inhibitor.
Will an increase in ILD cases scupper the AZD9291 plus durvalumab combination study in lung cancer? Will there be an advantage for Clovis or not?
Interview at ECC 2015 with Dr George Demetri on new developments in Soft Tissue Sarcoma
Interview with Dr Nora Disis about the phase 1b trial results for avelumab in ovarian cancer and the challenges of developing these agents in non-hypermutated tumour types
Commentary on Day 3 of the European Cancer Congress in Vienna
Commentary on Day 2 of the European Cancer Congress in Vienna
Highlights from Day 1 of the ECC 2015 (ECCO) meeting in Vienna
What happens when we literally step on the gas with immune agonists?
T cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) is widely expressed on immune cells. What's the potential for a TIM-3 checkpoint inhibitor?
Review of noteworthy abstracts at CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in New York
Holbrook Kohrt is a Stanford medical oncologist and clinical researcher who is leading the way in cancer immunotherapy combination strategies targeting CD137 (4-1BB).
Immunocore is an immuno-oncology company with an innovative approach to targeting T Cell Receptors (TCR) using their proprietary ImmTAC (Immune mobilising monoclonal TCRs against cancer) technology platform.
What's hot at ECCO 2015 in the oral sessions? An in-depth preview of what we can expect to hear about in Vienna...
What's hot in the 2015 ECCO late breaking abstracts in Vienna? Find out here...
Atezolizumab is expected to change the standard of care for the treatment of metastatic urothelial bladder cancer
Dr Carl June on progress of CAR T cell therapies in CLL, myeloma and solid tumours
We know that TILs can be effective in advanced melanoma, but what about common epithelial solid tumours? Can it work in these cancers too? Find out from Dr Rosenberg's latest work what's happening...
Oncolytic viruses are fast becoming a hot new area in cancer research but who are the players and where is this field going?
Exploring NY-ESO-1 as a valid target in sarcoma, multiple myeloma and metastatic melanoma...
Will checkpoint inhibitors make their mark in renal cell carcinoma and how will they be integrated into a treatment paradigm dominated by VEGF inhibitors?
Can we find new ways to target prostate cancer and other non-immunogenic tumours with immunotherapies? The answer may surprise...
Interview with Dr Rob Iannone of AstraZeneca on their IO pipeline
Interview with Dr William Pao on the Roche antibody based cancer immunotherapy strategy.
Editas presented some elegant work using their gene editing technology with CRISPR/Cas9 to modify T cells at ASGCT. Who would have guessed a short time afterwards Juno and Celgene would sign a 10 year collaboration?
ASCO 2015 interview with Dr James Gulley from NCI on Prostate Cancer Immunotherapy.
We've heard a lot about checkpoint immunotherapies in non-small cell lung cancer (NSCLC), but what about it's deadlier cousin, small cell lung cancer (SCLC)? Find out more...
Beyond the Big Four in checkpoint inhibitors, there is a raft of other companies anxious to get in the action. We take a look at Merck Serono and their progress with avelumab, an anti-PDL1 antibody
How do we help patients who are non-responders or have stable disease respond to checkpoint inhibitors? Will chemotherapy combos help or not?
Highlights from Monday at the 2015 ASCO annual meeting in Chicago
What's hot on Plenary Sunday at ASCO 2015? We'll be updating this blog post during the day.
Highlights from Day 2 at ASCO 15 in Chicago
Reflections on data presented in the first cancer immunotherapy press briefing at ASCO 2015
Do you need to incorporate a suicide suicide switch into CAR T cells that allows you to turn off the response, force the T cells to self-destruct?
Data at ASGCT and ASCO highlight potential new treatments in development for multiple myeloma
Update on checkpoint inhibitors in urothelial bladder cancer from AUA 2015 and what's in store for new developments with this disease.
First in a series of previews of ASCO 2015 annual meeting abstracts.
Dr Tom Gajewski is working on STING agonists that may have a major role to play in cancer immunotherapy.
At the 2015 annual meeting of the American Association of Immunologists (AAI) in New Orleans, leading experts shared their insights on the “Promise of Cancer Immunotherapy."
What are the hot checkpoint studies to watch out for at ASCO 2015? We created a cheat sheet to follow and track the data as tsunami hits...
What happens when we combine a checkpoint with an immune stimulant in advanced melanoma?
Beyond monotherapy with checkpoint inhibition, what combinations or sequences might be useful to explore next?
Beyond lung cancer and melanoma, what other tumour types represent the low hanging fruit for checkpoint monotherapy?
As the anti-PD-1 blockers show superiority in front-line metastatic melanoma, is this the end for Yervoy?
The annual meeting of the American Association for Cancer Research ended today. Find out what were our top 10 highlights.
Checkpoint Inhibitor data is a hot topic at AACR 2015. Data showed they may work in TNBC and also two checkpoints are better than one.
Cancer Immunotherapy is one of the hot topics at the 2015 AACR annual meeting in Philadelphia.
Does checkpoint blockade with CTLA4 have a role to play in hematologic malignancies?
University College London (UCL) is leading the way in European clinical trials of CAR T Cell therapies that target CD19.
Emerging data on different combinations with checkpoint inhibitors suggests that this may increase response rates and outcomes for cancer patients. Find out more...
Novartis have announced a deal with Aduro Biotech for access to their STING-targeted CDN platform technology.
The mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Novel targets are emerging in urothelial bladder cancer which may offer new therapeutic options for antibody and CAR-T cell therapy development.
Why is renal cell carcinoma so challenging from a clinical and sequencing perspective?
What is the potential of a new cell therapy with cytotoxic T lymphocytes against Epstein Barr Virus (EBV-CTL)?
Predictive biomarkers of response will be key to reimbursement of immunotherapies in Europe. One is potentially emerging for ipilimumab (Yervoy), which may be useful in speeding up access.
What are the emerging new trends in cancer immunotherapy? Beyond monotherapy lies many combination opportunities yet to be explored. At AACR in April, we will see a raft of novel approaches being discussed.
Will checkpoint inhibitors make an impact in hematologic malignancies or will novel combinations be needed?
Not all cancers respond to checkpoint inhibitors - how can we change that situation? Here's one example, using prostate cancer as a model...
Dr Krishna Komanduri discusses some of the best abstracts at the 2015 BMT Tandem meeting in San Diego.
Cellular Biomedicine Group (NASDAQ: CBMG) has acquired rights to the Chimeric Antigen Receptor T cell (CAR-T) therapy of the PLA General Hospital in Beijing.
What does the evolving landscape for CAR, TIL and TCR cell therapies look like?
The NCI have been at the forefront of developing novel cancer immunotherapies for several decades, but what is the current status of their groundbreaking work? Find out more in this primer on TILs.
What's the vision for Bellicum Pharmaceuticals? In an in-depth interview CEO Tom Farrell and COO Annemarie Moseley discuss the benefits offered by their new products in development.
What's next in immuno-oncology: what are potential ways to tackle the patients who do not respond to checkpoint immunotherapy?
What makes the Cellectis Chimeric Antigen Receptor CAR-T cell therapy different and what are the milestones expected in 2015?
Graft versus Host disease (GvHD) is an area of tremendous unmet medical need that is triggering the interest of a number of biotech and rare disease companies.
There is a lot of interest in checkpoint inhibitors, do they look they will be effective in Triple Negative Breast Cancer?
"Manic Monday" at the annual meeting of the American Society of Hematology features multiple oral sessions run at the same time!
Coverage of Day 2 of the annual meeting of the American Society of Hematology in San Francisco.
It's Day 1 of the 2014 annual meeting of the American Society of Hematology meeting in San Francisco.
ASH 2014 Multiple Myeloma data looks like it offers much promise for new treatments as well as an increasingly competitive marketplace
The science of targeting PD-1 and it's ligand PD-L1 in cancer immunotherapy is highlighted in five Letters published in Nature this week.
How can we jumpstart the immune system to enable more patients to respond? At SITC we learned more about targeting CD40 to achieve this.
At the SITC 2014 annual meeting, Dr van den Brink presented data on how the bacteria in our gut (the intestinal microbiome) can impact GvHD.
At the Society for Immunotherapy of Cancer (SITC) meeting last week, one of the Hot Topic sessions that took place after the conference formally ended was in managing the toxicities associated with chimeric antigen receptor T cell (CAR-T) therapy.
OX40 could be an exciting new target in immune-oncology that could be combined with checkpoint inhibitors to improve the T cell response.
Reflections on Day 1 of the 2014 annual meeting of the Society for Immunotherapy of Cancer (SITC).
Day 1 of the SITC annual meeting started with two workshops on immunotherapy and combination therapy
This week sees the start of the 2014 annual meeting of the Society for Immunotherapy of Cancer (SITC) at National Harbor, MD.
We’re excited to be attending this meeting for the first time.
There was a lot going on in lung, melanoma, renal and colorectal cancer in terms of immunotherapy in Madrid.
Merck announced their Breakthrough therapy designation for Keytruda in lung cancer this morning. What did we learn from the updated data for checkpoint inhibitors in NSCLC at ESMO that was different from ASCO?
Checkpoint inhibitors are looking very promising in advanced gastric cancer
At ESMO 2014, phase 1 clinical trial data in bladder cancer was presented for Pembrolizumab (Merck) and MPDL3280A (Roche/Genentech).
Genentech and NewLink announced a deal to license an IDO inhibitor. What's the impact of this on the IO pipeline?
Day 3 of the live blog from the ESMO 2014 Cancer Congress in Madrid.
Day 2 Live Blog with news and commentary on what's taking place at the ESMO Cancer Congress in Madrid
ESMO 2014 Cancer Congress data starts to roll out today - throughout the day we'll be updating the blog with initial impressions of data as it's presented.
Most of the abstracts for oral presentations at the forthcoming ESMO cancer congress in Madrid have just been released. This is a preview of some that caught my attention.
There are some interesting science symposia at #ESMO14 in both immunotherapy and targeted therapies. We review what the hot topics are here.
A review of the key poster and poster discussion abstracts on immunotherapy and targeted therapies at ESMO 2014
Update on what to watch out for in immunotherapy at ESMO 2014.
How will we decide which therapies to give patients with metastatic melanoma once the new immunotherapies are available?
Cellectis is a Paris based biotechnology company with a “blue ocean” strategy that, if successful, could revolutionize cancer immunotherapy.
After it's successful IPO, what are some of the challenges and opportunities facing Kite Pharma and their CAR-T cell immunotherapy?
AstraZeneca showed impressive data at ASCO 2014 for MEDI4736, a new anti PD-L1 immunotherapy.
There have been no new therapies in urothelial bladder cancer for 30 years - until now...
PD-1 antibodies nivolumab and pembrolizumab show considerable promise in metastatic melanoma. At ASCO 2014 we learnt more about how they compare against each other and their potential as a backbone for combinations.
What does the ASCO 2014 data show when you combine checkpoint inhibitors nivolumab and ipilimumab?
Insights on checkpoint inhibitors, co-stimulants, CAR T cell therapy and bispecific antibody TCRs
Update on emerging potential immuno-oncology biomarkers and combinations from AACR
This weekend at AACR a controversy emerged on the safety of Juno's CAR T cell therapy.
A review of innate immunotherapies including CD47, KIR, MICA and anti-glucan data at AACR in San Diego.
Much has been written about CAR T cells in B cell leukemias, but what about B cell lymphomas? Kite and the NCI had the honour of being the first to present data from ASH on their therapy in refractory DLBCL lymphomas
ASCO GU saw an update on the ipilimumab study in post chemotherapy CRPC. New biomarker data published this week in melanoma may be potentially useful in prostate and other tumour types.
Update on progress with anti-PD1 and PD-L1 immunotherapies in renal cell cancer. Where is the field going in this space?
Roche Genentech are developing their anti-PD-L1 as both monotherapy and also in combination with targeted therapies in lung, melanoma, renal and colon cancers. How is the early development progressing?
“We are at beginning of a REVOLUTION in immunotherapy,” said Elizabeth M. Jaffee, MD at the start of American Society of Clinical Oncology GastroIntestinal (ASCO GI) symposium keynote lecture on Immunologic Treatments for GI Cancers.
UPenn and CHOP are using genetically modified chimeric antigen receptor (CAR) T cells to treat patients with B cell cancers such as ALL, B cell NHL, CLL and other B cell malignancies.
At ASH, the impressive data from adult and pediatric ALL was presented.
This post includes insights on this approach and an interview with Dr Stephan Grupp on the pediatric data.
Immunotherapy continues to be a hot topic in oncology with anti-PD-1 and other new approaches being discussed at the AACR-IASLC meeting in San Diego
Start-up Juno Therapeutics is now in control of a legal dispute between St Jude Children’s Hospital and the University of Pennsylvania over chimeric antigen receptor (CAR) T cells intellectual property that contributed to the development of CTL019 licensed by Penn to Novartis. Penn are seeking to invalidate a St Jude patent that if upheld, CTL019 may infringe.
Juno Therapeutics is a start-up company with a mission to revolutionize the treatment of blood cancers through the use of chimeric antigen receptor (CAR) modified T cell therapy. The company recently launched with $120 million of series A funding. One of the scientific founders is Renier Brentjens MD, PhD, the Director of Cell Therapeutics at the Memorial Sloan-Kettering Cancer Center in NYC. He kindly gave an interview while at the ASH annual meeting in New Orleans.
Immuno-oncology is a hot topic at the moment and many new targets are emerging that may be useful in combination. This post discusses Innate Pharma's anti-KIR program in hematologic malignancies.
Chimeric Antigen Receptor T cell technology (CART) is an exciting new area, especially in hematologic malignancies. With the formation of a new start-up in Seattle, Juno Therapeutics, things just got very interesting...
An update on checkpoint inhibitors and CART from the AACR-NCI-EORTC Molecular Targets meeting - a lot of exciting possibilities are emerging!
Update on ALK (alectinib), PD-L1 (MEDI4736), PI3K (GDC-0980 and BKM120) and MEK (trametinib) inhibitors in solid tumours
A quick review of the check point immunotherapy abstracts from #ECC2013 in Amsterdam.
Overview of anti-PD-1 and PD-L1 immunotherapies plus ASCO 2013 data in melanoma and lung cancer.
For many attendees, the most exciting news at the 2012 annual meeting of the American Society of Hematology (ASH) held last December in Atlanta was the prospect of personalized T cell therapy for the treatment of patients with B cell cancers such as chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).